alphaparticleemitting radiopharmaceutical alpharadin 223racl2 days clinical development novel treatment skeletal metastases breast prostate cancer article summarizes current status preclinical clinical research 223racl2 potential advantages 223ra external beam irradiation registered bone seekers discussed published data 223ra dosimetry mice therapeutic study skeletal metastases model nude rats indicated significant therapeutic potential alphaemitters article provides results clinical single dosage trial present data repeated dosage study consecutive injections NUMBER body weight 3rd week injections NUMBER body weight NUMBER weeks apart furthermore interim results described randomized phase NUMBER trial involving NUMBER patients prostate cancer painful skeletal metastases received monthly injections 223ra saline adjuvant external beam radiotherapy lastly present preliminary dose estimates 223ra humans results indicate repeated dosing feasible toxicity low opportunities available combined treatment strategies references NUMBER bone seeking half life114 beta emitting bone seeking short term long term hormone refractory kbq kg kbq kg